Torrent Pharmaceuticals Limited
NSE:TORNTPHARM.NS
3199.85 (INR) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 107,280 | 94,640 | 84,188 | 78,862.3 | 77,800.1 | 74,618.4 | 58,572.7 | 56,721.7 | 65,193.9 | 45,788 | 40,323 | 30,485.1 | 25,944.106 | 21,219.676 | 19,160.378 | 16,306.576 | 13,548.483 | 12,987.854 | 9,671.624 | 5,477.527 |
| Cost of Revenue
| 54,780 | 27,350 | 25,374.7 | 22,353 | 22,525.2 | 23,216.7 | 17,768.2 | 18,885.7 | 16,479.8 | 14,745.6 | 13,004.8 | 9,679.1 | 9,813.293 | 6,965.301 | 5,709.752 | 5,352.463 | 3,203.291 | 4,534.933 | 3,647.337 | 1,930.535 |
| Gross Profit
| 52,500 | 67,290 | 58,813.3 | 56,509.3 | 55,274.9 | 51,401.7 | 40,804.5 | 37,836 | 48,714.1 | 31,042.4 | 27,318.2 | 20,806 | 16,130.813 | 14,254.375 | 13,450.626 | 10,954.113 | 10,345.192 | 8,452.921 | 6,024.287 | 3,546.992 |
| Gross Profit Ratio
| 0.489 | 0.711 | 0.699 | 0.717 | 0.71 | 0.689 | 0.697 | 0.667 | 0.747 | 0.678 | 0.677 | 0.682 | 0.622 | 0.672 | 0.702 | 0.672 | 0.764 | 0.651 | 0.623 | 0.648 |
| Reseach & Development Expenses
| 5,270 | 312.7 | 386.5 | 251.8 | 925.1 | 5,380 | 3,444.9 | 3,585.6 | 134 | 149.2 | 173.3 | 242.9 | 566.424 | 1,388.4 | 1,202.18 | 1,119.039 | 971.571 | 770.148 | 602.458 | 513.832 |
| General & Administrative Expenses
| 7,722.8 | 6,137.6 | 5,548.8 | 5,794 | 6,065.6 | 6,105 | 5,845.8 | 4,537.7 | 2,152.9 | 2,159.7 | 1,582.8 | 1,358.3 | 2,530.017 | 5,923.924 | 4,879.092 | 4,682.833 | 3,482.312 | 0 | 144.852 | 75.369 |
| Selling & Marketing Expenses
| 11,296.8 | 10,269.9 | 8,849.1 | 7,426.3 | 8,073.9 | 7,380.3 | 6,330.6 | 5,677 | 5,716.7 | 5,567.6 | 4,484 | 3,847.1 | 3,172.895 | 0 | 0 | 0 | 0 | 0 | 1,595.164 | 859.443 |
| SG&A
| 21,630 | 16,407.5 | 14,397.9 | 13,220.3 | 14,139.5 | 13,485.3 | 12,176.4 | 10,214.7 | 7,869.6 | 7,727.3 | 6,066.8 | 5,205.4 | 5,702.912 | 5,923.924 | 4,879.092 | 4,682.833 | 3,482.312 | 0 | 1,740.016 | 934.812 |
| Other Expenses
| 580 | 450 | 97.3 | 40.3 | 14 | 24.6 | 22.3 | 4.3 | 3.5 | 9.8 | 1.6 | 8.3 | -59.977 | 3,394.738 | 3,732.078 | 2,952.665 | 4,203.897 | 6,430.38 | 0.005 | 0.016 |
| Operating Expenses
| 26,900 | 45,940 | 41,119.9 | 38,225.6 | 40,086.4 | 37,715 | 31,398 | 26,997.4 | 23,616.2 | 22,748.2 | 17,793.2 | 14,542 | 11,653.434 | 10,707.062 | 9,813.35 | 8,754.537 | 8,657.78 | 7,200.528 | 5,193.031 | 2,989.526 |
| Operating Income
| 25,600 | 21,400.2 | 17,693.4 | 18,227.7 | 15,188.5 | 13,686.7 | 9,406.5 | 10,838.6 | 25,097.9 | 8,294.2 | 9,525 | 6,264 | 4,477.379 | 3,547.313 | 3,637.276 | 2,199.576 | 1,687.412 | 1,252.393 | 831.256 | 557.466 |
| Operating Income Ratio
| 0.239 | 0.226 | 0.21 | 0.231 | 0.195 | 0.183 | 0.161 | 0.191 | 0.385 | 0.181 | 0.236 | 0.205 | 0.173 | 0.167 | 0.19 | 0.135 | 0.125 | 0.096 | 0.086 | 0.102 |
| Total Other Income Expenses Net
| -2,080 | -2,928.6 | -5,434.3 | -2,965.1 | -3,322.8 | -8,070.1 | -96.4 | 42.3 | -1,460 | 1,103.9 | -1,085.2 | -448 | -891.261 | -120.565 | -165.092 | -277.72 | -196.425 | -162.024 | -54.216 | 11.209 |
| Income Before Tax
| 23,520 | 18,470 | 12,259.1 | 15,262.6 | 11,865.7 | 5,616.6 | 9,310.1 | 10,880.9 | 23,637.9 | 9,398.1 | 8,439.8 | 5,816 | 3,586.118 | 3,426.748 | 3,472.184 | 1,921.856 | 1,490.987 | 1,090.369 | 777.04 | 568.675 |
| Income Before Tax Ratio
| 0.219 | 0.195 | 0.146 | 0.194 | 0.153 | 0.075 | 0.159 | 0.192 | 0.363 | 0.205 | 0.209 | 0.191 | 0.138 | 0.161 | 0.181 | 0.118 | 0.11 | 0.084 | 0.08 | 0.104 |
| Income Tax Expense
| 6,960 | 6,020 | 4,487.3 | 2,743.8 | 1,618.5 | 1,253.5 | 2,528.7 | 1,545.1 | 6,413.8 | 1,888.4 | 1,800.7 | 1,466.9 | 723.151 | 725.094 | 1,160.231 | 78.16 | 144.22 | 155.237 | 187.827 | 81.056 |
| Net Income
| 16,563.8 | 12,452.3 | 7,771.8 | 12,518.8 | 10,247.2 | 4,362.8 | 6,781.1 | 9,335.5 | 17,223.8 | 7,509.4 | 6,638.8 | 4,327.6 | 2,840.355 | 2,701.695 | 2,311.953 | 1,843.696 | 1,346.767 | 935.132 | 508.627 | 487.619 |
| Net Income Ratio
| 0.154 | 0.132 | 0.092 | 0.159 | 0.132 | 0.058 | 0.116 | 0.165 | 0.264 | 0.164 | 0.165 | 0.142 | 0.109 | 0.127 | 0.121 | 0.113 | 0.099 | 0.072 | 0.053 | 0.089 |
| EPS
| 48.94 | 36.79 | 22.96 | 36.99 | 30.28 | 12.89 | 20.04 | 27.59 | 51.21 | 22.19 | 19.61 | 12.79 | 8.39 | 7.98 | 6.83 | 5.45 | 3.98 | 2.76 | 1.5 | 1.44 |
| EPS Diluted
| 48.94 | 36.79 | 22.96 | 36.99 | 30.28 | 12.89 | 20.04 | 27.59 | 51.21 | 22.19 | 19.61 | 12.79 | 8.39 | 7.98 | 6.83 | 5.45 | 3.98 | 2.76 | 1.5 | 1.44 |
| EBITDA
| 33,680 | 28,870 | 26,155.6 | 25,251.1 | 22,629.8 | 20,014.9 | 15,915.9 | 15,377.2 | 28,777.2 | 12,693.5 | 9,584.5 | 7,309 | 5,562.992 | 4,172.897 | 4,298.134 | 2,622.373 | 2,075.724 | 1,618.035 | 1,124.956 | 791.728 |
| EBITDA Ratio
| 0.314 | 0.305 | 0.311 | 0.32 | 0.291 | 0.268 | 0.272 | 0.271 | 0.441 | 0.277 | 0.238 | 0.24 | 0.214 | 0.197 | 0.224 | 0.161 | 0.153 | 0.125 | 0.116 | 0.145 |